Table 2 Clinical course of the studied patients.
From: Fluid restriction management in the treatment of COVID-19: a single-center observational study
Group 1 (N = 48) | Group 2 (N = 43) | Group 3 (N = 25) | |
|---|---|---|---|
HFNC, n (%) | 23 (47.9) | 12 (27.9) | 11 (44) |
MV duration, days | 6 (4–9) | 14 (10–17.5) | |
ECMO duration, days | 8 (6–11) | ||
Total dexamethasone, mg | 31 (3.5–46) | 54 (40–109) | 152 (59–559) |
Tocilizumab, n (%) | 7 (14.6) | 13 (30.2) | 8 (32) |
Baricitinib, n (%) | 1 (2.1) | 4 (9.3) | 5 (20) |
Tracheostomy, n (%) | 0 (0) | 5 (11.6) | 5 (20) |
Chest drainage, n (%) | 0 (0) | 7 (16.3) | 4 (16) |
HIT, n (%) | 0 (0) | 4 (9.3) | 5 (20) |
Packed red blood cell, mL | 560 (280–1400) | ||
Fresh frozen plasma, mL | 2400 (720–2880) | ||
Platelet, mL | 725 (450–800) | ||
Platelet, lowest, 103/μL | 189 (151–248) | 155 (108–245) | 86 (52–158) |
Highest Ferritin, ng/mL | 686.4 (392–1273.9) | 1032.6 (526.8–1683.2) | 1002.9 (576.5–1515.6) |
Highest d-dimer, μg/mL | 2.6 (2–4) | 4.6 (3.1–15) | 18.7 (8.1–26) |
Hospital LOS, days | 4.5 (2–7) | 10 (7–16) | 18 (15–26) |
In-hospital mortality, n (%) | 0 (0) | 7 (16.3) | 8 (32) |
